NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as an affordable growth stock based on our screening criteria. The company demonstrates strong growth potential, solid profitability, and a healthy financial position while maintaining a reasonable valuation. Below, we examine why NBIX fits this profile.

Growth Prospects

• Revenue Growth: NBIX reported a 24.81% increase in revenue over the past year, with an average annual growth rate of 24.48% in recent years.
• Earnings Outlook: Analysts expect earnings per share (EPS) to grow by 38.15% annually in the coming years, supported by a strong pipeline in neurological and neuropsychiatric treatments.
• Historical Performance: Despite a recent dip in EPS (-18.73% last year), the company has maintained a long-term EPS growth rate of 58.39% on average.

Valuation Considerations

• P/E Ratio: At 41.57, NBIX’s P/E ratio is high compared to the S&P 500 average (26.35), but it remains cheaper than 92.68% of its biotechnology peers.
• Forward P/E: The forward P/E of 19.10 is in line with the broader market and suggests a more reasonable valuation relative to future earnings.
• Enterprise Value/EBITDA: The ratio is favorable compared to industry peers, with NBIX priced cheaper than 94.64% of competitors.

Financial Health & Profitability

• Strong Margins: The company boasts a gross margin of 98.56% and an operating margin of 24.75%, both ranking among the top in the sector.
• No Debt: NBIX carries no debt, enhancing financial stability and flexibility.
• High ROIC: A return on invested capital (ROIC) of 13.20% outperforms 95.89% of industry peers, indicating efficient capital use.

For a deeper look at the company’s fundamentals, review the full analysis report.

Our Affordable Growth screener lists more stocks with similar characteristics and is updated daily.

Disclaimer

This is not investing advice! The article highlights observations at the time of writing, but you should conduct your own research before making investment decisions.